The present invention provides a novel amorphous Form of azilsartan acid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel crystalline Forms of azilsartan medoxomil, processes for their preparations and pharmaceutical compositions comprising them. The present invention further provides a novel amorphous Form of azilsartan medoxomil potassium, process for its preparation and pharmaceutical compositions comprising it. The present ...

The present invention describes novel crystalline form AL of Azilsartan medoxomil potassium, process for their preparation and pharmaceutical compositions containing them.

Provided processes for the preparation of (5-methyl-2-oxo-l3-dioxol-4-yl)methyl 2-ethoxyl- 1 - { [2 '-(5-oxo-45 -dihydro- 124-oxadiazol-3 -yl)biphenyl-4-yl]methyl } - 1 H-benzimidazole-7 -carboxylate its potassium salt and polymorphs thereof.

The present invention provides a novel crystalline Form of azilsartan acid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel crystalline Form of azilsartan medoxomil potassium, process for its preparation and pharmaceutical compositions comprising it.

The present invention relates to an improved process for the preparation of azilsartan or its esters or salts thereof. Specifically, the invention provides a method for the preparation of highly pure methyl 1-[[2'-(4,5-dihydro-5-oxo-4H-1,2,4-oxa-diazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate an intermediate compound of formula (4) for azilsartan medoxomil with reduced content of desethyl impurity. The invention also involves the use of highly pure methyl 1-[[2'-(4,5-di...

The present invention relates to an improved process for the preparation of azilsartan or its esters or salts thereof. Specifically the invention provides a method for the preparation of highly pure methyl 1-[[2'-(45-dihydro-5-oxo-4H-124-oxa-diazol-3-yl)biphenyl-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate an intermediate compound of formula (4) for azilsartan medoxomil with reduced content of desethyl impurity. The invention also involves the use of highly pure methyl 1-[[2'-(45-dihydro...

The present invention relates to novel solid state forms of azilsartan and azilsartan medoxomil monopotassium salt i.e. amorphous and crystalline forms of azilsartan and azilsartan medoxomil monopotassium salt and processes for the preparation thereof. The present invention also relates to co-precipitate of azilsartan. Further it relates to the pharmaceutical composition of amorphous and crystalline forms of azilsartan and azilsartan medoxomil monopotassium salt and its use.

The present solution relates to new forms of (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester of 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H- benzimidazole-7-carboxylic acid (azilsartan medoxomil) of formula I and a method of their preparation. The solution also relates to use of these new forms in preparing the potassium salt of azilsartan medoxomil.